TG Therapeutics Gestione
Gestione criteri di controllo 2/4
TG Therapeutics Il CEO è Mike Weiss, nominato in Dec2011, e ha un mandato di 12.92 anni. la retribuzione annua totale è $ 15.84M, composta da 5.5% di stipendio e 94.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.71% delle azioni della società, per un valore di $ 287.61M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 12.9 anni e 11 anni.
Informazioni chiave
Mike Weiss
Amministratore delegato
US$15.8m
Compenso totale
| Percentuale dello stipendio del CEO | 5.5% |
| Mandato del CEO | 12.9yrs |
| Proprietà del CEO | 5.7% |
| Durata media del management | 12.9yrs |
| Durata media del Consiglio di amministrazione | 11yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking
Nov 07
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | US$96m |
| Mar 31 2024 | n/a | n/a | US$41m |
| Dec 31 2023 | US$16m | US$875k | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
| Sep 30 2019 | n/a | n/a | -US$187m |
| Jun 30 2019 | n/a | n/a | -US$159m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$14m | US$656k | -US$173m |
| Sep 30 2018 | n/a | n/a | -US$150m |
| Jun 30 2018 | n/a | n/a | -US$148m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$10m | US$525k | -US$118m |
Compensazione vs Mercato: La retribuzione totale di Mike ($USD 15.84M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 7.74M ).
Compensazione vs guadagni: La retribuzione di Mike è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Mike Weiss (58 yo)
12.9yrs
Mandato
US$15,837,559
Compensazione
Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12.9yrs | US$15.84m | 5.71% $ 287.6m | |
| CFO, Corporate Secretary & Treasurer | 12.9yrs | US$1.87m | 0.48% $ 23.9m | |
| Senior Vice President of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Commercialization Officer | 6.4yrs | Nessun dato | Nessun dato |
12.9yrs
Durata media
Gestione esperta: Il team dirigenziale di TGTX è esperto e expertise (durata media dell'incarico 12.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12.9yrs | US$15.84m | 5.71% $ 287.6m | |
| Lead Independent Director | 12.6yrs | US$304.70k | 0.14% $ 7.3m | |
| Independent Director | 9.9yrs | US$264.70k | 0.18% $ 9.3m | |
| Independent Director | 12yrs | US$262.20k | 0.16% $ 7.9m | |
| Independent Director | 4.6yrs | US$259.70k | 0.070% $ 3.5m | |
| Independent Director | 9.4yrs | US$262.20k | 0.17% $ 8.4m |
11.0yrs
Durata media
58.5yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di TGTX è composto da personale esperto e esperto (durata media dell'incarico 11 anni).